Last reviewed 2026-04-23 · How we verify

Intradermal BCG SSI inj.

Intradermal BCG (Bacillus Calmette-Guérin) stimulates the immune system by activating innate and adaptive immunity to enhance anti-tumor or anti-infectious responses.

Intradermal BCG (Bacillus Calmette-Guérin) stimulates the immune system by activating innate and adaptive immunity to enhance anti-tumor or anti-infectious responses. Used for Non-muscle invasive bladder cancer (established use), Melanoma or other solid tumors (investigational).

At a glance

Mechanism of action

BCG is a live attenuated mycobacterium that triggers pattern recognition receptors on immune cells, promoting Th1 and Th17 cell differentiation, macrophage activation, and enhanced cytotoxic T-cell responses. This immunostimulation has been used clinically for bladder cancer and is being investigated for other malignancies and infectious diseases. The intradermal route delivers the vaccine to skin-resident immune cells for systemic immune priming.

Approved indications

• Non-muscle invasive bladder cancer (established use)
• Melanoma or other solid tumors (investigational)

Common side effects

• Local injection site reaction (erythema, induration)
• Fever
• Fatigue
• BCG-itis (systemic infection, rare)

Key clinical trials

• A Study of GC3107(BCG Vaccine) in Healthy Infants (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Intradermal BCG SSI inj. CI brief — competitive landscape report
• Intradermal BCG SSI inj. updates RSS · CI watch RSS
• Green Cross Corporation portfolio CI